Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2022-07-19 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物首次公开发行股票并在科创板上市招股说明书
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus for an initial public offering (IPO) and listing on the Shanghai Stock Exchange Science and Technology Innovation Board (科创板). It includes extensive information about the company's business, risks, product pipeline, financial data, litigation risks, and governance. The document is titled '招股说明书' which translates to 'Prospectus' or 'Offering Circular'. This type of document is typically filed as part of capital raising and listing activities. It is not an earnings release, annual report, or management discussion, but rather a detailed disclosure document for a new stock issuance and listing. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP), which covers updates on company fundraising and capital structure changes such as IPO prospectuses.
2022-07-19 Chinese
益方生物首次公开发行股票并在科创板上市网下初步配售结果及网上中签结果公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of shares by 益方生物科技（上海）股份有限公司 on the Shanghai Stock Exchange's STAR Market (科创板). It includes information about the offline preliminary allotment results, online lottery results, strategic placement, subscription details, allotment quantities, subscription obligations, and related procedures. The document references regulatory approvals from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and it provides extensive data on investors, subscription numbers, and allotment results. This is not a financial report like an annual or interim report, nor is it a transcript, audit, or management report. It is a formal announcement of the results of the IPO allotment and subscription process, including the lottery results and payment instructions. Therefore, it fits best into the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as IPOs.
2022-07-17 Chinese
益方生物首次公开发行股票并在科创板上市网上发行申购情况及中签率公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the subscription situation and lottery results for the initial public offering (IPO) of shares by 益方生物科技（上海）股份有限公司 on the STAR Market (科创板). It details the number of shares issued, subscription rates, allocation mechanisms, and payment instructions. It does not contain financial statements or detailed financial performance data, nor is it a full report like an annual or interim report. It is a formal announcement related to capital issuance and share allocation for the IPO. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3117 characters, which is consistent with an announcement rather than a full report.
2022-07-14 Chinese
中信证券股份有限公司关于益方生物科技（上海）股份有限公司首次公开发行股票战略投资者之专项核查报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report issued by a sponsoring institution (中信证券股份有限公司) regarding the strategic investors involved in the initial public offering (IPO) of 益方生物科技（上海）股份有限公司 on the STAR Market (科创板). It includes extensive information about the approval process, board and shareholder meetings, regulatory approvals from the Shanghai Stock Exchange and China Securities Regulatory Commission, detailed descriptions of strategic investors, their qualifications, share allotments, lock-up periods, and compliance with relevant regulations. The document is titled as a "专项核查报告" (Special Inspection Report) related to the IPO strategic investors. It is not a general annual or quarterly report, nor an earnings release or a call transcript. It is not a simple announcement but a comprehensive compliance and verification report related to the IPO process and strategic investor participation. This type of document fits best under the category of Capital/Financing Update (CAP), as it deals with the issuance of new shares, strategic investor allotments, and related financing activities for the IPO.
2022-07-12 Chinese
益方生物首次公开发行股票并在科创板上市投资风险特别公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of shares by 益方生物科技（上海）股份有限公司 on the Shanghai Stock Exchange's STAR Market (科创板). It includes information about the issuance price, number of shares, underwriting, subscription procedures, pricing rationale, risk factors, and regulatory approvals. The document is not a financial report like an annual or interim report, nor is it a transcript or management report. It is a detailed capital market announcement related to the company's fundraising and issuance of new shares. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (6900 characters) and content confirm it is a substantive announcement, not a brief notice or a report publication announcement.
2022-07-12 Chinese
益方生物首次公开发行股票并在科创板上市发行公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of shares by 益方生物科技（上海）股份有限公司 on the Shanghai Stock Exchange's Science and Technology Innovation Board (科创板). It includes information about the issuance, pricing, investor participation, allotment, subscription dates, underwriting, strategic placement, and regulatory compliance references. The document is regulatory in nature, related to capital raising and stock issuance, and contains detailed data on the offering process, pricing, and investor allocations. It is not a financial report like an annual or quarterly report, nor is it a transcript, audit report, or management report. It is not a simple announcement of a report publication but a substantive disclosure about the capital issuance and financing activity. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-07-12 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.